Published in Ann Rheum Dis on February 01, 1980
The use of laboratory tests in the diagnosis of SLE. J Clin Pathol (2000) 1.92
Factor VIII related antigen in the assessment of vasculitis. Ann Rheum Dis (1987) 1.43
Immune complexes in early arthritis. L Detection of immune complexes before rheumatoid arthritis is definite. Clin Exp Immunol (1981) 1.21
Acute-phase proteins and serum immunoglobulins in ankylosing spondylitis. Ann Rheum Dis (1983) 1.19
C-reactive protein in patients with bacteremia. J Clin Microbiol (1984) 1.17
Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis. Am J Physiol Renal Physiol (2009) 1.06
A novel pathogenetic concept-antiviral immunity in lupus nephritis. Nat Rev Nephrol (2012) 1.01
High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. Semin Arthritis Rheum (2008) 1.00
Clinical and laboratory studies of arthritis in leprosy. BMJ (1989) 0.96
Relationship between urinary sialylated saccharides, serum amyloid A protein, and C-reactive protein in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis (1982) 0.95
CRP/anti-CRP antibodies assembly on the surfaces of cell remnants switches their phagocytic clearance toward inflammation. Front Immunol (2011) 0.95
Serum C-reactive protein measurement in the detection of intercurrent infection in Oriental patients with systemic lupus erythematosus. Ann Rheum Dis (1985) 0.91
Lack of the long pentraxin PTX3 promotes autoimmune lung disease but not glomerulonephritis in murine systemic lupus erythematosus. PLoS One (2011) 0.90
C-reactive protein and serological indices of disease activity in systemic lupus erythematosus. Ann Rheum Dis (1983) 0.89
Amyloidosis and systemic lupus erythematosus. Ann Rheum Dis (1984) 0.87
Genetic variation in C-reactive protein (CRP) gene may be associated with risk of systemic lupus erythematosus and CRP concentrations. J Rheumatol (2008) 0.83
C-reactive protein inhibits plasmacytoid dendritic cell interferon responses to autoantibody immune complexes. Arthritis Rheum (2013) 0.82
A subset of systemic lupus erythematosus with progressive cystic bone lesions. Ann Rheum Dis (1990) 0.80
Bilirubin levels in patients with systemic lupus erythematosus: increased or decreased? Rheumatol Int (2011) 0.77
Possible involvement of interferon alfa in the pathogenesis of fever in systemic lupus erythematosus. Ann Rheum Dis (1989) 0.76
"Normal" acute phase response in systemic sclerosis. Br Med J (Clin Res Ed) (1984) 0.75
Serum C-reactive protein concentrations in Nova Scotia Duck Tolling Retrievers with immune-mediated rheumatic disease. Acta Vet Scand (2017) 0.75
Elevated Erythrocyte Sedimentation Rate Is Predictive of Interstitial Lung Disease and Mortality in Dermatomyositis: a Korean Retrospective Cohort Study. J Korean Med Sci (2016) 0.75
The natural history of systemic lupus erythematosus by prospective analysis. Medicine (Baltimore) (1971) 4.65
Rheumatoid arthritis: relation of serum C-reactive protein and erythrocyte sedimentation rates to radiographic changes. Br Med J (1977) 3.97
Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci U S A (1977) 3.13
Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol (1978) 3.06
Serum amyloid P-component is an acute-phase reactant in the mouse. Nature (1979) 2.49
Analogues in other mammals and in fish of human plasma proteins, C-reactive protein and amyloid P component. Nature (1978) 2.18
Isolation of amyloid P component (protein AP) from normal serum as a calcium-dependent binding protein. Lancet (1977) 2.09
Interaction of C-reactive protein with lymphocytes and monocytes: complement-dependent adherence and phagocytosis. J Immunol (1976) 2.02
Isolation of C-reactive protein by affinity chromatography. Clin Exp Immunol (1977) 1.97
Radioimmunoassay of human C-reactive protein and levels in normal sera. J Lab Clin Med (1976) 1.95
Stimulating effect of C-reactive protein on phagocytosis of various species of pathogenic bacteria. Clin Exp Immunol (1971) 1.93
Interactions of C-reactive protein with the complement system. II. C-reactive protein-mediated consumption of complement by poly-L-lysine polymers and other polycations. J Exp Med (1975) 1.88
C-reactive protein in systemic lupus erythematosus. Arthritis Rheum (1977) 1.52
Determination of C-reactive protein in serum as a guide to the treatment and management of rheumatic fever. Am J Med (1953) 1.34
A fluorescent immunoassay for the quantification of C-reactive protein. J Immunol Methods (1978) 1.23
Quantitative measurement of C-reactive protein in serum. Clin Chim Acta (1969) 1.11
Cx-Reactive protein response in rabbits during immunization with foreign proteins. J Immunol (1960) 0.97
STUDIES OF ACUTE PHASE PROTEIN. III. ELICITATION OF CX-REACTIVE PROTEIN IN RELATION TO IMMUNE ELIMINATION OF ANTIGEN AND APPEARANCE OF CIRCULATING ANTIGEN-ANTIBODY COMPLEXES. J Immunol (1964) 0.88
The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med (1994) 8.10
The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med (1995) 8.08
International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum (1999) 7.67
Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol (1983) 7.47
Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol (1997) 7.27
Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet (1983) 6.71
Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) (1984) 6.40
Significance of anti-D.N.A. antibodies in systemic lupus erythematosus. Lancet (1971) 6.22
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ (2000) 6.10
C-reactive protein fifty years on. Lancet (1981) 5.93
Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature (1997) 5.47
Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed) (1983) 5.04
Particulate air pollution is associated with an acute phase response in men; results from the MONICA-Augsburg Study. Eur Heart J (2001) 4.21
Systemic lupus erythematosus. Lancet (2001) 4.18
Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med (1999) 3.88
Anti-DNA activity in systemic lupus erythematosus. A diagnostic and therapeutic guide. Ann Rheum Dis (1971) 3.76
Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis (1987) 3.62
Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J (Clin Res Ed) (1983) 3.53
Anti-phospholipid antibodies. Clin Rheum Dis (1985) 3.43
Pulmonary hypertension in systemic lupus erythematosus. Br Med J (Clin Res Ed) (1983) 3.39
The anticardiolipin syndrome. J Rheumatol (1986) 3.36
Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med (1990) 3.17
The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) (1989) 3.13
Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol (1978) 3.06
Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol (1987) 3.02
Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest (1993) 2.92
Role of complement in induction of the allergic response. Nat New Biol (1972) 2.90
Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility. Br Med J (Clin Res Ed) (1983) 2.86
Solid phase radioimmunoassays for human C-reactive protein. Clin Chim Acta (1981) 2.77
Concern about safety of carotid angioplasty. Stroke (1996) 2.73
Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet (2001) 2.71
Activation of mouse complement by different classes of mouse antibody. Immunology (1979) 2.68
The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure (1999) 2.64
Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care (2000) 2.63
Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet (1980) 2.63
Effect of alcohol consumption on systemic markers of inflammation. Lancet (2001) 2.52
Cerebral infarction in systemic lupus: association with anticardiolipin antibodies. Clin Exp Rheumatol (1985) 2.51
Serum amyloid P-component is an acute-phase reactant in the mouse. Nature (1979) 2.49
Complement dependence of localisation of aggregated IgG in germinal centres. Scand J Immunol (1975) 2.48
Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest (1982) 2.48
Role of complement in induction of antibody production in vivo. Effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses. J Exp Med (1974) 2.45
Quantitative fecal indium 111-labeled leukocyte excretion in the assessment of disease in Crohn's disease. Gastroenterology (1983) 2.37
Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med (1986) 2.35
Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med (1982) 2.33
Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum (1997) 2.31
Role of C3 in in vitro lymphocyte cooperation. Nature (1974) 2.27
C-reactive protein and coronary heart disease: a critical review. J Intern Med (2008) 2.25
Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am J Med (1989) 2.23
Role of complement in the induction of immunological responses. Transplant Rev (1976) 2.21
Analogues in other mammals and in fish of human plasma proteins, C-reactive protein and amyloid P component. Nature (1978) 2.18
Long-term survival in systemic amyloid A amyloidosis complicating Crohn's disease. Gastroenterology (1997) 2.18
C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med (1999) 2.17
Isolation of human C-reactive protein and serum amyloid P component. J Immunol Methods (1982) 2.15
Systemic lupus erythematosus. A prospective analysis. Ann Rheum Dis (1978) 2.12
Clinical endpoints in peripheral endovascular revascularization trials: a case for standardized definitions. Eur J Vasc Endovasc Surg (2008) 2.10
Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet (1982) 2.10
Amyloidosis. Histopathology (1994) 2.10
Isolation of amyloid P component (protein AP) from normal serum as a calcium-dependent binding protein. Lancet (1977) 2.09
Minocycline-induced arthritis. Clin Exp Rheumatol (1998) 2.09
Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol (1979) 2.08
Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J (1982) 2.07
Thrombocytopenia in SLE and related autoimmune disorders: association with anticardiolipin antibody. Br J Haematol (1985) 2.07
Structure of pentameric human serum amyloid P component. Nature (1994) 2.07
Isolation of serum amyloid P-component (protein SAP) in the mouse. Immunology (1979) 2.07
Low back pain in schoolchildren. An epidemiological study. Scand J Rehabil Med (1988) 2.05
Phylogenetic aspects of C-reactive protein and related proteins. Ann N Y Acad Sci (1982) 2.03
Sjögren's syndrome and autoimmunity in a geriatric population. Age Ageing (1972) 2.01
Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. Nat Med (2001) 1.99
Isolation of C-reactive protein by affinity chromatography. Clin Exp Immunol (1977) 1.97
C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM (2003) 1.93
Affinity purified anti-cardiolipin and anti-DNA antibodies. J Clin Lab Immunol (1985) 1.92
Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J (1999) 1.87
Three dimensional structure of human C-reactive protein. Nat Struct Biol (1996) 1.87
Acute synovial rupture of the knee--a differential diagnosis from deep vein thrombosis. Proc R Soc Med (1970) 1.85
Diaphragm function and lung involvement in systemic lupus erythematosus. Am J Med (1977) 1.83
Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A (1995) 1.83
C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation (2001) 1.81
Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus (1998) 1.80
Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component. J Exp Med (1998) 1.78
Recurrent deep vein thrombosis and Addison's disease in "primary" antiphospholipid syndrome. J Rheumatol (1989) 1.77
A novel variant of transthyretin, 59Thr-->Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family. Circulation (1995) 1.77
Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses. J Mol Biol (1997) 1.77
Sjogren's syndrome. 2. Clinical associations and immunological phenomena. Q J Med (1973) 1.77
Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol (1996) 1.76
Central nervous system lupus--diagnosis and treatment. J Rheumatol (1980) 1.75
Oxygen-15 brain scanning for detection of cerebral involvement in systemic lupus erythematosus. Lancet (1978) 1.75
Neuropsychiatric problems in systemic lupus erythematosus. Br Med J (1972) 1.74
Antiphospholipid antibodies: a risk factor for occlusive ocular vascular disease in systemic lupus erythematosus and the 'primary' antiphospholipid syndrome. Ann Rheum Dis (1989) 1.73
Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. Kidney Int (1998) 1.71
Amyloid P component is located on elastic fibre microfibrils in normal human tissue. Nature (1981) 1.70
The effect of protein restriction on the progression of renal insufficiency. N Engl J Med (1989) 1.70
The protofilament substructure of amyloid fibrils. J Mol Biol (2000) 1.69
Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br Med J (Clin Res Ed) (1984) 1.68
Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. Immunology (1982) 1.67
Diversity of autoantibodies in primary biliary cirrhosis and chronic active hepatitis. Clin Exp Immunol (1984) 1.67
Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) (1999) 1.66
Biology of serum amyloid P component. Ann N Y Acad Sci (1982) 1.65